Mouse KLK7 / Kallikrein 7 Protein (His Tag)

Sino Biological Inc. liefert Mouse KLK7 / Kallikrein 7 Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Mouse KLK7 / Kallikrein 7 Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/KLK7-Kallikrein-7-Protein-g-9876.html

Produkt-Information von KLK7 / Kallikrein 7 Protein

QC Testing von KLK7 / Kallikrein 7 Protein

Purity >(71.4+26)% as determined by SDS-PAGE SDS-PAGE: KLK7 protein Bio-activity Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (AnaSpec, Cat#27114). The specific activity is >70 pmoles/min/μg. Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method Stability Samples are stable for up to twelve months from date of receipt at -70℃ Predicted N terminal Gln 22 Molecular Mass The recombinant mouse KLK7 comprises 239 amino acids and has a predicted molecular mass of 26.5 kDa. The apparent molecular mass of the protein is approximately 31 and 34 kDa in SDS-PAGE under reducing conditions due to glycosylation. Formulation Lyophilized from sterile PBS, pH7.4 Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von KLK7 / Kallikrein 7 Protein

Verwandte Produkte & Themen von KLK7 / Kallikrein 7 Protein

Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>Kallikrein>>KLK7/Kallikrein 7

Cancer>>Angiogenesis>>Kallikrein>>KLK7/Kallikrein 7

Beschreibung von KLK7 / Kallikrein 7 Protein

Kallikrein-7, also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to the peptidase S1 family and Kallikrein subfamily. Members of the Kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14). Kallikrein-7 / KLK7 appears to be increased in ovarian cancer and higher KLK7 expression in ovarian cancer tissue is associated with poorer prognosis of ovarian cancer patients. Kallikrein-7 / KLK7 is abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Kallikrein-7 / KLK7 is up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at the protein level). It was significantly associated with shorter overall survival (OS) and disease-free survival (DFS). Kallikrein-7 / KLK7 may catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. KLK7 also plays a role in the activation of precursors to inflammatory cytokines.

References

1. Dong Y. et al., 2003, Clin Cancer Res. 9 (5): 1710-20.
2. Kyriakopoulou LG. et al., 2003, Clin Biochem. 36 (2): 135-43.
3. Talieri M. et al.,2004,Thromb Haemost. 91 (1): 180-6.
4. Talieri M. et al., 2009, Thromb Haemost. 101 (4): 741-7.